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Dilated cardiomyopathy (DCM) is a progressive heart
disease characterized by left ventricular dilation and
contractile dysfunction. Although many candidate
genes have been identified with mouse models, few
of them have been shown to be associated with
DCM in humans. Germline depletion of Ncoa6, a nu-
clear hormone receptor coactivator, leads to embry-
onic lethality and heart defects. However, it is unclear
whether Ncoa6 mutations cause heart diseases in
adults. Here, we report that two independent mouse
models of NCOA6 dysfunction develop severe DCM
with impaired mitochondrial function and reduced
activity of peroxisome proliferator-activated recep-
tor d (PPARd), an NCOA6 target critical for normal
heart function. Sequencing of NCOA6-coding re-
gions revealed three independent nonsynonymous
mutations present in 5 of 50 (10%) patients with idio-
pathic DCM (iDCM). These data suggest that mal-
function of NCOA6 can cause DCM in humans.INTRODUCTION
Dilated cardiomyopathy (DCM), characterized by cardiac
enlargement and systolic dysfunction, is the most common
form of cardiomyopathy, accounting for up to 30%–40% of all
heart failure cases (Towbin and Bowles, 2002). Although DCM
has diverse causes, approximately half of cases are idiopathic
(iDCM). Clinical investigations have shown that approximately40% of patients with iDCM exhibit the patterns of autosomal-
dominant inheritance, implying that genes play an important
role in DCM pathogenesis (Hershberger et al., 2010). Hence,
the search for novel susceptibility loci is a major challenge in
DCM research.
Nuclear receptor coactivator 6 (or NCOA6, also known as
ASC-2, NRC, TRBP, PRIP, and RAP250) is ubiquitously ex-
pressed in diverse tissues including the heart and stimulates
the transcriptional activity of various transcription factors and
nuclear hormone receptors (NRs) by coordinating with cofactors
(Mahajan and Samuels, 2008). NCOA6 possesses two LXXLL
motifs required for interaction with NRs. The first LXXLL motif
of NCOA6 can interact with almost all liganded NRs, whereas
more restricted NRs can bind to the second LXXLL motif. In
mice, germline mutation of Ncoa6 induces growth retardation
and developmental defects in the heart, liver, brain, and
placenta, resulting in embryonic lethality between embryonic
days 8.5 (E8.5) and 12.5 (Antonson et al., 2003; Kuang et al.,
2002; Mahajan et al., 2004; Zhu et al., 2003). Overexpression
of the dominant-negative version of the gene (DN1) incompletely
suppresses endogenous NCOA6 activity, allowing mice to sur-
vive, but to develop several defects including cataract, atrial
thrombosis, and hypertrophy at the later stage (Kim et al., 2002).
Peroxisome proliferator-activated receptors (PPARs) are the
members of the NR superfamily that regulate fatty acid meta-
bolism and mitochondrial function (Barger and Kelly, 2000;
Wang et al., 2010). The transcriptional activity of PPARs is
elevated or induced upon ligand binding and is regulated further
by coactivators and corepressors (Guan et al., 2005; Viswa-
karma et al., 2010). PPARd (also called PPARb) is expressed at
high levels in the heart and is essential for normal heart function
(Cheng et al., 2004). In a mouse model, cardiomyocyte-specificCell Reports 8, 991–998, August 21, 2014 ª2014 The Authors 991
PPARd knockout leads to DCM; however, whether an associa-
tion between PPARd polymorphisms and DCM exists in humans
remains unknown.
RESULTS
Overexpression of DN1 Causes DCM in Mice
Germline Ncoa6 deficiency results in embryonic lethality with
several developmental defects (Antonson et al., 2003; Kuang
et al., 2002; Mahajan et al., 2004; Zhu et al., 2003). We produced
transgenic (Tg) mouse lines overexpressing DN1 (849–929 resi-
dues containing an N-terminal LXXLL-1 motif of NCOA6, Figures
S1A and S1B) that are able to reach adulthood, although these
animals are prone to diverse defects (Kim et al., 2002). Among
nine DN1-Tg lines, four founder mice (#71, #84, #87, and #104)
expressed DN1 in their hearts (representative expression of
DN1 is shown for founder #87 in Figure S1C). The progenies of
founder #87 died prematurely at 20 weeks old (Figure S1D).
Anatomical examination revealed cardiac enlargement and
increased heart-to-body weight ratios with frequent pericardial
effusion (Figures S1E–S1H). The progenies of founders #71,
#84, and #104 exhibited similar phenotypes, which were absent
in wild-type (WT) and mutant DN1-Tg mice in which the LXXLL-1
motif had been mutated to LXXAA (Kim et al., 2002). These phe-
notypes closely resembled those of DCM (Towbin and Bowles,
2002). Given that DN1 would be expected to compete with the
binding of other coactivators for liganded NRs and multiorgan
defects were found in DN1-Tg mice, it is unclear whether DN1
specifically blocks the activity of endogenous NCOA6 and
causes DCM through cardiac cells only. For instance, we found
multiple phenotypes such as fatty liver, thymic and spleen atro-
phy, lung hypoplasia, kidney hyperplasia, and brain defects in
DN1-Tg mice (Kim et al., 2002).
Cardiomyocyte-Specific Ablation of NCOA6 Leads to
DCM in Mice
To confirm the heart-specific function of NCOA6, we generated
cardiomyocyte-specific Ncoa6-deficient (D/D) mice by employ-
ing floxed Ncoa6 alleles (f/f) and a Cre recombinase transgene
specific for differentiated cardiomyocytes under the control
of the a-myosin heavy-chain promoter (a-MHC-Cre-Tg) (Agah
et al., 1997; Zhu et al., 2003). Compared to control mice (f/f),
NCOA6 mRNA and protein levels were significantly decreased
in a heart-restrictive manner in D/D mice (Figures 1A and 1B).
These mice demonstrated Mendelian inheritance and showed
no significant cardiac developmental defects. Consistent with
the phenotypes observed in DN1-Tg mice, D/D mice showed
premature death, increased heart weight-to-body weight ratios,
and cardiac dilatation (Figures 1C, 1D, and S2A–S2D). The
increased heart weight was caused by atrial thrombi, whereas
there was no alteration in the weight of the ventricle (Figure S2C).
Histological examination of the hearts ofD/Dmice revealed com-
mon features of DCM, including enlarged ventricular cavities
with thin walls and reactive myocardial fibrosis (Figures 1D, 1E,
and S2D). Notably, Ncoa6 heterozygous knockout mice (D/+)
also exhibited the characteristics of DCMwith late onset (Figures
S2E–S2I), indicating thatNcoa6 haploinsufficiency is sufficient to
precipitate DCM in mice. Consistent with the previous reports by992 Cell Reports 8, 991–998, August 21, 2014 ª2014 The AuthorsAgah et al. (1997) and Cheng et al. (2004), we could not find any
significant differences of cardiac functions in a-MHC-Cre-Tg
mice, compared to the f/f mice (data not shown). These results
demonstrate that loss or insufficiency of NCOA6 function directly
causes DCM.
Comparative transthoracic echocardiographic analysis re-
vealed severe dilatation of the left ventricle (LV) and decreased
contractility without a significant alteration in heart rate in D/D
mice at 4 months of age (Figure 1F). Left ventricular end-systolic
dimensions (LVESDs) and end-diastolic dimensions were
enlarged 1.72- and 2.35-fold, respectively, compared to control
mice (Figure 1G). Ejection fraction (EF) and fractional shortening,
two direct measures of cardiac contractile function, were pro-
foundly diminished compared to control mice (Figures 1H and
S2J). Impaired cardiac function was also evident in D/+ and
DN1-Tgmice (Figures S1I–S2L). Increased expression of cardiac
hypertrophy markers, including atrial natriuretic peptide (Anp)
and a- to b-MHC isoform switching (Reiser et al., 2001), were
found in 12- and 20-week-old, but not 4-week-old, D/D mice
(Figures S2M–S2O). Furthermore, the hearts of 12-week-old
mice displayed hypertrophic phenotype (Figure S2P), suggest-
ing that concentric hypertrophy transiently proceeds prior to
the onset of DCMphenotype. Thus,Ncoa6 defects progressively
compromise overall cardiac function in mice.
Impaired Cardiac Ultrastructure and Mitochondrial
Function in NCOA6-Deficient Mice
To examine potential mechanisms in the development of DCM,
ultrastructural examination of cardiac tissues with transmission
electron microscopy (TEM) was conducted and showed disarray
of sarcomeres and mitochondria in the hearts of D/D mice (Fig-
ure 2A). The number ofmitochondria was significantly decreased
in the hearts of D/D mice (Figure 2B). In addition, reduced
mitochondrial content was confirmed by measuring DNA, RNA,
and respiratory chain protein levels, and impaired activity
of mitochondrial complex II was evident in D/D and D/+ mice
(Figures 2C–2F). These results suggest that NCOA6 is essen-
tial for the maintenance of normal mitochondrial function in
cardiomyocytes.
NCOA6 Deficiency Impairs PPARd Activity in
Cardiomyocytes
Because PPARd, one of the major targets of NCOA6, is crucial
for mitochondrial biogenesis and cardiomyocyte-specific
knockout of Ppard causes spontaneous DCM in mice (Cheng
et al., 2004; Wang et al., 2010), we hypothesized that depletion
of NCOA6 alters PPARd activity. To further explore the role of
NCOA6 in PPARd-mediated transactivation, we measured tran-
script levels of PPARd targets in the mouse heart. Levels of key
molecules involved in fatty acid oxidation (Cheng et al., 2004),
such as muscle-type carnitine palmitoyltransferase-1 (Mcpt-1),
Cd36, Fatp1, pyruvate dehydrogenase lipoamide kinase,
isozyme 4 (Pdk4), and uncoupling protein 3 (Ucp3), were consid-
erably decreased even though no significant difference in Ppard
transcript levels was observed between D/D and f/f hearts (Fig-
ures 3A–3C). Similar to cardiomyocyte-specific knockout of
Ppard (Cheng et al., 2004), D/D mouse showed cardiac lipid




Figure 1. Premature Death and Impaired Cardiac Function in Cardiomyocyte-Specific Ncoa6 Knockout Mice
(A) Western blot analysis of NCOA6 in the hearts of 1-month-old f/f and D/D male mice. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a
loading control.
(B) Real-time quantitative PCR analysis ofNcoa6mRNA in various organs of 1-month-old f/f and D/Dmale mice. Br, brain; He, heart; Li, liver; Ki, kidney; Lu, lung;
Sp, spleen. Ncoa6 mRNA levels were normalized to those of Gapdh. Graphs show mean ± SD. *p < 0.05.
(C) Kaplan-Meier survival curves of f/f (male, n = 34; female, n = 34) andD/D (male, n = 21; female, n = 39) mice. Genders and genotypes are labeled inside the plot.
M, male; F, female. ***p < 0.001.
(D) Gross morphology (top) and histological examinations (bottom; hematoxylin and eosin staining [H&E]) of hearts from 4-month-old female f/f andD/Dmice. RV,
right ventricle. Scale bars, 2.5 mm.
(E) H&E (top) and Masson’s trichrome staining (bottom) of LVs from 4-month-old female mice. Scale bars, 100 mm.
(F–H) Representative profiles of M-mode echocardiographic analyses (F) and quantitative representations of LVESD and left ventricular end-diastolic dimension
(LVEDD) (G) and percent fractional shortening (H) of f/f (male, n = 3; female, n = 4) and D/D (male, n = 3; female, n = 3) mice. Graphs showmean ± SD. ***p < 0.001.
See also Figures S1 and S2.that NCOA6 deficiency results in dysfunctional activity of PPARd
and fatty acid metabolism. Interestingly, increased expressions
of estrogen receptor alpha (ERa) and its target genes were found
in the D/D mouse hearts (Figures S3B–S3D).
We also found that Cre-mediated Ncoa6 deficiency attenu-
ated the induction of PPARd targets by the selective PPARd
agonist GW501516 (GW) in neonatal primary cardiomyocytes
(Figures 3D–3G). In addition, in the AC16 human cardiomyocyte
cell line, small hairpin RNA (shRNA)-mediated NCOA6 knock-
down (Figures 3H and 3I) reduced GW-induced activation ofPPARd and its target genes (Figures 3J–3M), indicating that
PPARd requires NCOA6 for optimal transactivation of its target
genes.
Nonsynonymous Mutations of NCOA6 in Patients with
iDCM
To find the relevance of NCOA6-mediated DCM pathogenesis to
human iDCM, we screened the entire NCOA6-coding sequence
in patients with iDCM and identified four nonsynonymous substi-




Figure 2. Cardiomyocyte-Specific Ncoa6
Deficiency Impairs Cardiac Ultrastructures
and Mitochondrial Function in Mice
(A) TEM analysis of LVs from 3-month-old f/f and
D/D female mice. Scale bars, 2 mm. Arrowheads
point to Z discs; arrows point to mitochondria.
(B and C) Quantification of the number of mito-
chondria (mito.) per 36 mm2 calculated from three
independent TEM images (B) andmtDNA contents
(C) by Southern blot analyses in the hearts of
3-month-old male and female mouse ventricles
(n = 3 for each genotype). Graphs show mean ±
SD. *p < 0.05; ***p < 0.001.
(D) Analyses of mitochondrial rRNAs (12S and
16S), mRNAs (ND1 and COXI), and tRNAs (F, L1,
P, C, and Q) by northern blot. p < 0.05 for all
mitochondrial RNAs (mtRNAs). LVs of 3- to
5-month-old male and female mice (n = 3 for each
genotype) were used.
(E) Analysis of mitochondrial respiratory chain
complexes II, III, and V by western blot (left) and its
quantitative ratios (right) of each complex to lamin
A (LMNA). LVs of 3- to 5-month-old male and
female mice (n = 3 for each genotype) were used.
LMNA was used as a loading control. Graphs
show mean ± SD. **p < 0.01; ***p < 0.001.
(F) Analysis of mitochondrial complex II activity in
2- to 3-month-old mice (male, n = 3; female, n = 4
for each genotype). mOD, mitochondrial optical
density. Graphs show mean ± SD. **p < 0.01.c.2430G > A, G703E; c.2618A > T, M766L; and c.3848A > G,
T1176A). P239R was found in both patients without DCM and
patients with iDCM, indicating that this is not a DCM-causing
mutation. Rather, it appears to be a SNP that is specific to the
Korean population. This SNP is not found among American pop-
ulations (Table S1) (Fu et al., 2013). G703E and M766L muta-
tions were found in one patient each, and three patients were
harboring the T1176A mutation (total 10%; Table S1). These 3
mutations were absent in 403 Korean healthy subjects, and
only 1 subject showed T1176A mutation among the 6,502
American populations (Figures 4A and 4B; Table S1) (Fu et al.,
2013), suggesting that 3 variants are potent DCM-related muta-
tions in humans. G703E and T1176A were located in regions of
the NCOA6 gene that are highly conserved across species (Fig-
ure 4C), whereas Macaca mulatta encodes leucine rather than
methionine at human M766 position, suggesting that M766L
substitution might not be harmful. All five patients possessed
one WT allele.
The effects of each NCOA6 mutation on the protein confor-
mation were estimated with the protein structure-prediction
software (Buchan et al., 2010; Cheng et al., 2005). The G703E
substitution appeared to induce remarkable structural deforma-
tions by transforming coiled-coil and b sheet structures into
an a helix (Figure S4A). Furthermore, in silico evaluation with994 Cell Reports 8, 991–998, August 21, 2014 ª2014 The AuthorsPolyPhen-2 and SIFT software showed
a potentially deleterious effect of G703E
on NCOA6 function: PolyPhen score of
0.999; SIFT score of 0.006 (Adzhubei
et al., 2010; Ng and Henikoff, 2003).Although M766L and T1176A substitutions were predicted to
induce no structural change and be benign (PolyPhen-2 score
of 0 in both, and SIFT score of 0.039 and 0.289 in M766L and
T1176A, respectively), we could not exclude the possibility that
M766L and T1176A substitutions are also deleterious for
NCOA6 functions. T1176A transcript level was similar to those
of the NCOA6 WT and its other mutants, but its protein level
was significantly low (Figures S4B and S4C), though its mecha-
nism is inconclusive.
BecausedepletionofNcoa6 leads todecreased transcriptional
activity of PPARd in mice, we examined whether NCOA6 variants
alter the activity PPARd. In fact, overexpression of G703E and
T1176A significantly suppressed the activation of a PPARd
and its targets including CD36 and FATP1 in the AC16 parental
and NCOA6 knockdown cells upon the treatment with GW (Fig-
ures 4D–4F and S4D). However, no remarkable difference was
observed between WT and M766L mutant NCOA6, implying
that M766L may not be a pathogenic mutation for DCM, though
further investigation is required to clarify its physiological effect.
Altogether, these data suggest that two substitutions (G703E
and T1176A, if M766L is not) perturb NCOA6-PPAR signaling
via distinct mechanisms: G703E causes structural and functional
defects, whereas T1176A reduces the expression of PPARd
targets possibly by destabilizing NCOA6 proteins.
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Figure 3. NCOA6 Is Required for Normal Transcriptional Activity of PPARd
(A and B) Transcript levels of PPARd targets in the LVs of f/f (white; male, n = 1; female, n = 2) and D/D (black; male, n = 1; female, n = 2) mice. Graphs show
mean ± SD. *p < 0.05; **p < 0.01.
(C) mRNA levels of PPARd in the hearts of f/f and D/D mice (n = 3 per each genotype). Gapdh was used as a loading control. NS, not statistically significant.
(D) Semiquantitative PCR analyses of Ncoa6 in primary cardiomyocytes, transduced with lentivirus encoding GFP or Cre constructs, isolated from the f/f
mouse heart.
(E–G) Transcript levels of Cd36 (E), Fatp1 (F), and Pdk4 (G) in f/f primary cardiomyocytes containing GFP or Cre constructs. Treatment with GW lasted 48 hr.
Graphs show mean ± SD. *p < 0.05.
(H–M) Transcript and protein levels of NCOA6were examined by real-time quantitative PCR (H) and western blot (I). Parental (Pa), no transfection; shGFP, shRNA
against GFP; shNCOA6 #3 and #5, independent shRNA constructs against NCOA6. (J) Relative PPAR response element (PPRE)-luciferase activity. Treatment
with GW lasted 24 hr. (K–M) Transcript levels ofCD36 (K), FATP1 (L), andMCPT-1 (M) were measured by real-time quantitative PCR analyses after treatment with
GW for 48 hr. Graphs show mean ± SD.
See also Figure S3.DISCUSSION
Ncoa6 deficiency reduces the number of mitochondria in car-
diac tissue. Cardiac abnormality of mitochondrial function is
closely associated with DCM pathogenesis (Marin-Garciaet al., 1995). In addition, impaired expression of Ncoa6 has
been found in muscle fibers with a dysfunctional electron trans-
port system (Herbst et al., 2013). Thus, Ncoa6mutations appear
to induce a loss of or suppress biogenesis of mitochondria in





Figure 4. Nonsynonymous Mutations of NCOA6 in Human Patients with iDCM Result in Impaired PPARd Activity
(A) DNA sequences of NCOA6 exons that were obtained from patients with iDCM. Red arrows indicate mutation sites. Glu, glutamate; Leu, leucine; Ala, alanine;
Gln, glutamine; Gly, glycine; Met, methionine; Thr, threonine.
(B) Schematic representation of the human NCOA6 protein. AD, activation domain; STL, serine, threonine, and leucine-rich region. Blue asterisks indicate
mutation sites.
(C) NCOA6 amino acid sequence alignment across eight species. Numerals indicate the positions of the amino acid mutations (red) in patients.
(D–F) Relative luciferase activity of PPRE (D) and gene expression levels of CD36 (E) and FATP1 (F) in WT and mutant NCOA6-transfected AC16 cells with or
without treatment with GW for 48 hr. Graphs show the mean of triplicate experiments ± SD. NS, not statistically significant; Veh, vehicle. *p < 0.05; **p < 0.01.
See also Figure S4 and Table S1.
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ASC-2 complex (ASCOM), which is essential for proper
NR transactivation (Mahajan and Samuels, 2008). Because
NCOA6 stimulates NR transactivation activity, it is reasonable
to expect altered downstream signaling of NRs to play a role
in the mechanism for DCM. Here, we provide the potent evi-
dence linking abnormal NR signaling to human DCM pathogen-
esis. Consistent with previous studies reviewed by Mahajan and
Samuels (2008), our results indicate that depletion of NCOA6
expression results in remarkably reduced PPARd activity both
in vitro and in vivo.
Germline loss of Ncoa6 leads to embryonic lethality with mul-
tiple organ dysfunction including the placenta (Antonson et al.,
2003; Kuang et al., 2002; Zhu et al., 2003). The homozygous
null mutation of Ncoa6 precipitates cardiac developmental
abnormalities at E10.5, suggesting that NCOA6 might still be
essential for early cardiac development before this stage (Kuang
et al., 2002). Because a-MHC-Cre starts to function at E14.5,
a-MHC-Cre-mediated depletion ofNcoa6might not be sufficient
to cause early cardiac developmental defects.
It appears that NCOA6 mutations may disrupt diverse NR
transactivation via an effect on ASCOM. In fact, another obser-
vation suggests that NR pathways other than PPARd may be
affected by NCOA6 mutations (Mahajan and Samuels, 2008).
Our findings imply that additional NRs might be influenced by
NCOA6 impairment. In support of these findings, it has been
shown that mutations in mixed-lineage leukemia (MLL) 2/4 and
tryptophan (W)-aspartic acid (D) repeat domain (WDR) 5, which
are also components of ASCOM, are likely to be involved in
congenital heart disease (Zaidi et al., 2013). This evidence indi-
cates that Ncoa6 deficiency significantly alters the activity of
the NRs, resulting in DCM.
A recent study in mice revealed that NCOA6 promotes ubiqui-
tination-mediated degradation of ERa, whereas Ncoa6 defi-
ciency causes ERa accumulation in uterine stromal cells during
the preimplantation period (Kawagoe et al., 2012). Consistent
with these findings, we observed that the expression of ERa
and its target genes was significantly increased in Ncoa6 D/D
mice prior to DCM pathogenesis. Interestingly, it is common
for ERa expression to increase in patients with end-stage DCM
(Mahmoodzadeh et al., 2006). Based on these lines of evidence,
we hypothesized that the expression and/or function of NCOA6
may be suppressed prior to the onset of clinical DCMmanifesta-
tions, possibly accelerating the progression of the disease.
Taken together, our findings will manifest stepping forward to a
more accurate diagnosis of human DCM.EXPERIMENTAL PROCEDURES
Animals
All animal experiments were performed in accordance with Korean Food and
Drug Administration guidelines. Protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of the Yonsei University (YLARC
2008-0014). Mice that had been backcrossed to the FVB/NTac strain for at
least nine generations were used and maintained in the specific pathogen-
free facility of the Yonsei Laboratory Animal Research Center.
Primary Cardiomyocyte Culture
Primary cardiomyocytes were isolated as previously described by Crone et al.
(2002).Human Genomic DNA Mutation Analysis
Each subject was provided with written informed consent to participate in the
study according to the guidelines of the institutional review board (4-2007-
0234). Exon scanning of all NCOA6 (NM_014071)-coding regions and splice
junction sites was performed by direct sequencing.
Echocardiogram
Echocardiography was performed with the echocardiographic system (Vivid 7;
GE Medical Systems) equipped with a 12 MHz transducer. Mice with shaved
chests were anesthetized with isoflurane (Hana Pharmaceutical) and placed
on a platform. End-systolic and end-diastolic dimensions were measured
using M-mode echocardiogram imaging that was obtained at the papillary
muscle level for the measurement of LV wall thickness and LV dimensions.
We captured these images over more than ten cardiac cycles, and the data
shown are averages from at least three cardiac cycles per image acquisition.
These procedures were performed at least three times, and average values
were determined for each mouse.
Statistical Analyses
Statistical significance was determined using the two-tailed Student’s t test.
Data were analyzed with GraphPad Prism (GraphPad Software). p values
less than 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.07.027.
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